Retatrutide in South Africa: 2026 trial results and timeline

What is retatrutide?

Retatrutide is an investigational once-weekly injection developed by Eli Lilly for obesity and related conditions. It activates three hormone receptors at the same time: GLP-1, GIP and glucagon, which is why it is called a triple agonist. No regulator anywhere has approved it for routine use yet.

The receptor list places it in a familiar family. Semaglutide, the molecule in Ozempic and Wegovy, works on the GLP-1 receptor alone. Tirzepatide, the dual-action molecule in Mounjaro, adds GIP. Retatrutide adds a third receptor, glucagon, which raises the body's energy use alongside the appetite and blood sugar effects of the other two.

That third receptor is the scientific bet behind the molecule: curb intake on one side and lift energy expenditure on the other. Lilly developed it under the code LY3437943, and it is dosed once a week by injection, like the registered medicines in the class. The difference sits in the pharmacology, not the routine.

Is retatrutide available in South Africa?

No. Retatrutide is not registered with SAHPRA, no South African application has been announced, and no regulator worldwide has approved it. No licensed pharmacy in the country can lawfully dispense it, and outside a clinical trial there is no legal way to use it anywhere.

SAHPRA put it plainly to the Mail & Guardian in July 2026: the medicine "is still under clinical investigation" and is not approved for routine sale in any market. That statement outranks every website and WhatsApp seller claiming otherwise.

South Africa does have registered options in this medicine family. Wegovy, Mounjaro and Saxenda hold SAHPRA registrations for weight management, while Ozempic is registered for type 2 diabetes. Which medicine covers what, and how treatment works here, is set out in our guide to GLP-1 in South Africa.

What do the TRIUMPH trial results show?

The TRIUMPH programme has reported the largest average weight loss of any phase 3 obesity trials to date. In TRIUMPH-1, adults taking the 12 mg dose lost an average of 28.3% of their body weight over 80 weeks, and 45.3% of them lost 30% or more. Individual results vary.

TRIUMPH-1 enrolled 2,339 adults with obesity, or overweight plus at least one weight-related condition, and excluded people with diabetes. All three studied doses, 4 mg, 9 mg and 12 mg, met the trial's endpoints. Participants with a starting BMI of 35 or more who continued into an extension reached an average loss of 30.3% at 104 weeks.

The programme did not start there. A phase 2 trial published in the New England Journal of Medicine in 2023 recorded 24.2% average loss at 48 weeks on the 12 mg dose across 338 adults, the result that first separated retatrutide from the rest of the pipeline. Loss of around 30% of body weight is territory previously associated with bariatric surgery, which is why the phase 3 readouts drew headlines well beyond the medical press.

Retatrutide trial results at a glance

All figures are averages from separate placebo-controlled trials with different designs and populations, so they do not stack into a single ranking. Individual results vary. TRIUMPH-4 also reported large reductions in knee pain alongside the weight loss, which is why knee osteoarthritis sits in Lilly's planned registration package.

How does retatrutide compare with semaglutide and tirzepatide?

No head-to-head trial has compared retatrutide with either molecule, so no one can rank them with confidence yet. Its trial averages are higher: 28.3% in TRIUMPH-1 against around 21% for tirzepatide in SURMOUNT-1 and 14.9% for semaglutide in STEP 1. Cross-trial comparisons are unreliable, and individual results vary.

The class has already shown why a direct trial matters. Semaglutide and tirzepatide were compared across their separate trials for years before SURMOUNT-5 ran the actual head-to-head and measured 20.2% against 13.7% at 72 weeks. Our semaglutide vs tirzepatide comparison unpacks that result and what it changed.

Retatrutide has no equivalent trial, and it will not have one for years. Until then, the numbers describe trial populations, not a contest. If retatrutide ever reaches South African practice, the right option will be decided by a doctor on assessment.

When will retatrutide be approved?

Eli Lilly plans to submit retatrutide to the US FDA in the first quarter of 2027, covering obesity, obstructive sleep apnoea and knee osteoarthritis pain. Reviews of new molecules typically run close to a year, so the earliest plausible US approval lands in late 2027 or in 2028.

Lilly says it has the clinical data to support those first submissions and is still completing the manufacturing part of the dossier. None of the schedule is guaranteed: filings slip, and regulators ask questions.

A US or European approval would not change anything in South Africa by itself. What it does is build the dossier a manufacturer can bring to SAHPRA, and reliance pathways let SAHPRA lean on those completed reviews rather than repeat them, which matters for the local timeline below.

When could retatrutide arrive in South Africa?

No South African date exists, and none can exist yet: SAHPRA review only starts once the manufacturer submits an application here, and Eli Lilly has not announced one. Counting a US filing in early 2027, a registration review after that, and then a launch decision, the realistic wait is measured in years.

The recent record sets expectations. SAHPRA reviews have sped up since its old application backlog cleared, and reliance on completed FDA or EMA reviews can shorten them further. Even so, Wegovy's injection took about four years from first US approval to South African pharmacy shelves.

Registration is also not the same thing as launch. The Wegovy pill, approved in the US in December 2025, still has no announced South African timeline, and Rybelsus, a semaglutide tablet registered here in 2024, has never been launched locally. Retatrutide will join that queue behind its own paperwork, and any firm local date you see before Lilly announces one is invented.

Why is retatrutide already for sale in South Africa?

Because unregistered sellers are not waiting for the law to catch up. Mail & Guardian reporting in July 2026 found products labelled retatrutide sold openly through Instagram, Facebook, classified sites and gym networks, packaged to look clinical and often stamped "research grade" or "not for human consumption".

Those stamps are the tell. A vial sold for injection while labelled not for human consumption is a seller's attempt to sidestep the Medicines Act, not a quality standard. SAHPRA's response has been enforcement: seized stock, criminal cases opened, surveillance of online seller platforms and coordination with customs.

Demand explains the supply. Trial headlines travel faster than regulatory timelines, and sellers fill the gap with products that no inspector, pharmacist or doctor ever checks.

What is wrong with "research peptide" retatrutide?

Everything that matters about it is unverified: contents, strength, sterility and storage. SAHPRA warns that peptides bought from social media, online vendors, gyms or informal suppliers are likely counterfeit or substandard, and lists infection from injectable use among the documented risks. Its advice to anyone who has bought a product marketed as retatrutide is to stop using it and report the seller.

Professor Zaheer Bayat, an endocrinologist quoted in the Mail & Guardian's reporting, lists the concrete risks: infection from non-sterile products, toxicity from contaminants, incorrect dosing with nobody monitoring, and breakdown of the peptide from poor storage. None of that shows on the outside of a professional-looking box.

Even the genuine trial medicine is still being characterised. TRIUMPH-4 flagged dysaesthesia, abnormal skin sensations such as tingling or prickling, in up to 20.9% of participants on the top dose. Inside a trial, that gets monitored and followed up; alone with a grey-market vial, nobody is watching. The same caution applies to compounded and copycat GLP-1 products in South Africa, where enforcement is already active. Side effects from any such product can be reported to SAHPRA at adr@sahpra.org.za.

What does retatrutide cost in South Africa?

Retatrutide has no lawful South African price, because an unregistered medicine cannot be sold here at all. Medicine prices are set through the Single Exit Price system only after SAHPRA registration, so every rand figure attached to retatrutide today comes from an unregistered seller, not a pharmacy.

Those figures do circulate. The Mail & Guardian reported a Johannesburg gym seller asking around R3,000 for a month's supply in mid 2026. That number tells you what the grey market charges for an unverified substance; it says nothing about what a registered medicine would cost. We do not sell medicine. Prices vary by pharmacy and dose; confirm with your pharmacy.

For scale once registration eventually happens, our guide to what GLP-1 treatment costs in South Africa covers the published prices of the registered medicines in this class. Where a future retatrutide price would sit is unknown until a Single Exit Price is published.

Can you buy retatrutide at Dischem or Clicks?

No. Dischem, Clicks and every licensed South African pharmacy can only dispense medicines registered with SAHPRA, and retatrutide is not one of them. A website quoting a Dischem price for retatrutide, or claiming pharmacy stock, is describing something that does not lawfully exist.

When registration eventually happens, the route will look like the one for the current weight loss injections: a doctor assesses you and confirms a treatment plan, and a licensed pharmacy dispenses the medicine at its published price. Until then, there is no legitimate counter to ask at, in person or online.

What are retatrutide's side effects?

The most common side effects across the trials were nausea, vomiting, diarrhoea and constipation, mostly mild to moderate and concentrated around dose increases. That matches the registered GLP-1 medicines. TRIUMPH-4 added a newer signal: dysaesthesia in up to 20.9% of people on the 12 mg dose, generally mild.

The phase 2 trial also recorded a small average rise in heart rate, largest around week 24 and easing after that. Findings like these are why phase 3 programmes and regulatory reviews exist: the full safety picture, including who should not take it, is still being assembled, and pregnancy safety in particular has not been established.

Whatever that picture turns out to be, retatrutide would arrive in South Africa as a scheduled medicine: doctor assessment first, dispensing by a licensed pharmacy, follow-up while doses change. Severe, persistent stomach pain on any medicine in this class can signal pancreatitis: seek medical care immediately.

What are the registered options while you wait?

South Africa already has registered weight loss medicines: Wegovy (semaglutide), Mounjaro (tirzepatide) and Saxenda (liraglutide) hold SAHPRA registrations for weight management. Ozempic contains semaglutide too but is registered for type 2 diabetes, not weight loss. Each carries its own evidence, side effects and exclusions.

Waiting years for an unregistered molecule is rarely a better plan than treating obesity with what is registered now, particularly when the waiting version on offer is a grey-market vial. A doctor's assessment weighs your health history against each registered option, and what to expect from doctor-led treatment covers how that process runs.

If retatrutide reaches SAHPRA registration with its trial results intact, it will join that assessment conversation as one more option, and moving across from an existing medicine would be a doctor-managed change. Treat the condition with what is registered now, and let the paperwork run on its own schedule.

Frequently asked questions